Dynamic regulatory features of the protein tyrosine kinases

Neha Amatya1, David Yin-Wei Lin1, Amy H Andreotti2

  • 1Roy J. Carver Department of Biochemistry, Biophysics and Molecular Biology, Iowa State University, Ames, IA 50011, U.S.A.

Insights

Understanding non-receptor tyrosine kinase (Src module kinases) regulation requires dynamic motion insights. Dynamic networks and specific behaviors influence kinase activation, crucial for developing targeted therapies.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Structural Biology

Background:

  • Non-receptor tyrosine kinases, including SRC, TEC, and C-terminal SRC Kinase families, are critical in cellular signaling and disease.
  • Crystal structures offer static insights, but dynamic motions are key to kinase regulation and activation.

Purpose of the Study:

  • To review how dynamic motions and conformational ensembles of non-receptor tyrosine kinases influence their activation.
  • To highlight the importance of dynamic regulation in kinase function and drug discovery.

Main Methods:

  • Review of existing literature focusing on structural and dynamic studies of Src module kinases.
  • Analysis of how conformational ensembles and dynamic motions affect kinase activity.

Main Results:

  • Kinase regulation is better understood through dynamic motions, not just static structures.
  • Shared regulatory dynamic networks exist across kinase families, with unique dynamics for specific kinases.
  • Intrinsically dynamic regions play significant, yet underexplored, regulatory roles.

Conclusions:

  • Understanding kinase dynamics is essential for advancing drug discovery and combating resistance.
  • Defining conformational ensembles and dynamic allostery will be key for future kinase-targeted therapies.

Related Concept Videos

Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.0K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

4.4K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
18.1K
Cis-regulatory Sequences02:02

Cis-regulatory Sequences

Cis-regulatory sequences are short fragments of non-coding DNA that are present on the same chromosomes as the genes that they regulate. These fragments serve as binding sites for transcriptional regulators, proteins that are responsible for controlling gene transcription and differential gene expression across cell types in eukaryotes. Cis-regulatory sequences can be close to the gene of interest or thousands of bases away in the DNA sequence; however, those sequences that are further away are...
11.6K
Cis-regulatory Sequences02:02

Cis-regulatory Sequences

4.0K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
461